Clinical Pharmacokinetics and Pharmacodynamics
Clinical pharmacokinetics and pharmacodynamics is the quantitative study of what the body does to a drug and what the drug does to the body. Pharmacokinetics describes the time course of absorption, distribution, metabolism, and excretion (ADME) that governs drug concentration, while pharmacodynamics relates that concentration to the magnitude and time course of the drug's effect. Together they provide the conceptual framework for understanding drug behaviour in patients.
Definition
Pharmacokinetics is the study of the time course of drug and metabolite concentrations in body fluids and tissues, characterized by absorption, distribution, metabolism, and excretion; pharmacodynamics is the study of the relationship between drug concentration and biological effect.
Scope
This area orients the reader to the core processes that link an administered dose to a clinical effect: absorption and bioavailability, distribution and protein binding, hepatic metabolism, renal elimination and clearance, and the dose-response relationships of pharmacodynamics. It treats these as reference and educational topics in clinical pharmacy, not as a source of dosing or individualized treatment recommendations.
Sub-topics
Core questions
- How does an administered dose translate into a concentration-time profile in the body?
- Which ADME processes determine how much drug reaches the systemic circulation and how long it persists?
- How is drug concentration linked quantitatively to the intensity and duration of effect?
- What patient and drug factors create variability in exposure and response?
Key concepts
- Absorption, distribution, metabolism, excretion (ADME)
- Bioavailability
- Volume of distribution
- Clearance
- Half-life
- Steady-state concentration
- Concentration-effect relationship
- Therapeutic window
Key theories
- Clearance concept
- Clearance is defined as the volume of fluid cleared of drug per unit time and serves as the primary parameter relating dosing rate to steady-state concentration; it is additive across eliminating organs and largely independent of distribution.
- Link (effect-compartment) PK/PD model
- Sheiner and colleagues introduced a hypothetical effect compartment to account for the delay (hysteresis) between plasma concentration and effect, allowing pharmacokinetics and pharmacodynamics to be modelled simultaneously.
Mechanisms
After administration, a drug is absorbed into the systemic circulation, distributed among plasma and tissue compartments according to its physicochemical properties and protein binding, and eliminated by hepatic metabolism and renal excretion. The resulting concentration-time profile is summarized by parameters such as bioavailability, volume of distribution, clearance, and half-life. Pharmacodynamics then maps concentration onto effect, classically through a sigmoid Emax (Hill) relationship, with clearance providing the bridge that links a maintenance dosing rate to steady-state exposure.
Clinical relevance
Understanding pharmacokinetics and pharmacodynamics underpins the interpretation of drug-concentration data, the rationale for therapeutic drug monitoring, and the appreciation of how disease and physiology alter drug exposure. The material here describes general principles for educational use and is not a basis for individual dosing or treatment decisions, which require qualified clinical judgement.
Evidence & guidelines
The conceptual foundations are codified in standard reference texts of clinical pharmacology and pharmacokinetics, while regulatory agencies publish technical guidance on bioavailability, drug interactions, and exposure-response analysis that operationalizes these principles for drug development.
History
Quantitative pharmacokinetics emerged in the mid-twentieth century as analytical chemistry made serial concentration measurement feasible. Gerhard Levy's work on the kinetics of pharmacologic effects connected concentration to response, Rowland and Benet's clearance concepts gave the field its central organizing parameter, and Sheiner's modelling united kinetics and dynamics, establishing the integrated PK/PD framework used today.
Key figures
- Malcolm Rowland
- Leslie Benet
- Lewis Sheiner
- Gerhard Levy
- Thomas Tozer
Related topics
Seminal works
- rowland-1973
- sheiner-1979
Frequently asked questions
- What is the difference between pharmacokinetics and pharmacodynamics?
- Pharmacokinetics describes how the body handles a drug over time (absorption, distribution, metabolism, excretion), whereas pharmacodynamics describes how the drug acts on the body, relating concentration to effect.
- Why is clearance considered the most important pharmacokinetic parameter?
- Clearance relates the dosing rate to the steady-state concentration; because it is additive across eliminating organs and relatively independent of distribution, it determines the maintenance dose needed to reach a target exposure.